NCT06773910
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06773910
Title BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS) (TIGOS-LS)
Acronym TIGOS-LS
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors SCRI Development Innovations, LLC
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.